CLERVONAFUSP ALFA
UNII I6M9Q08XBP

Substance Identification & Data

This profile provides standardized clinical and technical data for Clervonafusp Alfa, uniquely identified by the FDA Unique Ingredient Identifier (UNII) I6M9Q08XBP.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2145123-44-8 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code
I6M9Q08XBP
CAS Registry Number
2145123-44-8
RxNorm Concept ID
N/A

Detailed Substance Profile

Preferred Name
CLERVONAFUSP ALFA
Official standardized name for this substance within the FDA UNII nomenclature system.
NCI Thesaurus
C169858
National Cancer Institute reference terminology for clinical and research data.
INN ID
10973
Sequential identifier assigned via the WHO International Nonproprietary Name program.
USAN ID
HI-62
Identifier assigned by the United States Adopted Names Council.
Substance Type
protein
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Clervonafusp Alfa. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

CLERVONAFUSP ALFA

Common Names & Synonyms

CLERVONAFUSP ALFA [INN]
CLERVONAFUSP ALFA [USAN]
IMMUNOGLOBULIN G1, (HUMANIZED MONOCLONAL 3E10 .GAMMA.1-CHAIN FAB FRAGMENT) FUSION PROTEIN WITH 67-952-LYSOSOMAL .ALPHA.-GLUCOSIDASE (HUMAN RECOMBINANT), DISULFIDE WITH HUMANIZED MONOCLONAL 3E10 .KAPPA.-CHAIN
IMMUNOGLOBULIN G1-KAPPA, CELL-PENETRATING HUMANIZED FAB FRAGMENT TARGETING THE EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2 (DELAYED-EARLY RESPONSE PROTEIN 12SOLUTE CARRIER FAMILY 29 MEMBER 2) FUSED WITH HUMAN LYSOSOMAL ALPHA-GLUCOSIDASE (ACID MALTASEAGLUCOSIDASE ALFAEC=3.2.1.20): .GAMMA.1 SHORT HUMANIZED MONOCLONAL ANTIBODY (1-224) (VH (IGHV3-48*01 (90%) (IGHD)-IGHJ4*01 (93%)) (8.8.9) (1-116)-HOMO SAPIENS IGHG1*01 (HINGE(DEL(11-15)), CH2(DEL), CH3(DEL)) (117-224)) FUSION PROTEIN WITH DIGLYCYLSERYLBIS(TRIGLYCYLSERYL)DIGLYCYL (LINKER 225-237) AND WITH HUMAN PRO-LYSOSOMAL ALPHA-GLYCOSIDASE (40-925-PEPTIDE) (238-1123) (219-218')-DISULFIDE WITH .KAPPA. LIGHT CHAIN (1'-218') (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV1-39*01 (82%) IGKJ2*02 (82%))(10.3.9) (1'-111')-HOMO SAPIENS IGKC*01 (112'-218')), PRODUCED IN CHO CELLS, GLYCOFORM ALFA
IMMUNOGLOBULIN G1-KAPPA, CELL-PENETRATING HUMANIZED FAB FRAGMENT TARGETING THE EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2 (ENT2), FUSED WITH A HUMAN LYSOSOMAL .ALPHA.-GLUCOSIDASE FRAGMENT, GLYCOFORM ALFA

Technical Codes

VAL1221
VAL-1221

External Clinical & Regulatory Resources

CAS
Common Chemistry
NCATS
Inxight Drugs
NLM
DailyMed Products
NCATS
GSRS Full Record
NIH
NCI Thesaurus